Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARWR NASDAQ:ASND NYSE:QGEN NYSE:RDY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARWRArrowhead Pharmaceuticals$27.73+2.1%$19.00$9.57▼$29.34$3.83B12.03 million shs2.39 million shsASNDAscendis Pharma A/S$202.90-1.1%$183.33$111.09▼$208.16$12.42B0.39490,017 shs329,996 shsQGENQIAGEN$47.08-1.1%$48.65$37.63▼$51.88$10.47B0.641.39 million shs903,884 shsRDYDr. Reddy's Laboratories$14.61+2.5%$14.36$12.26▼$16.19$12.20B0.321.77 million shs679,598 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARWRArrowhead Pharmaceuticals-6.57%+23.33%+65.47%+60.11%+22.28%ASNDAscendis Pharma A/S-0.34%+5.64%+7.17%+19.07%+72.24%QGENQIAGEN+0.17%+2.32%-0.84%+2.97%+10.11%RDYDr. Reddy's Laboratories-0.49%+0.49%+3.26%-10.22%-9.94%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARWRArrowhead Pharmaceuticals$27.73+2.1%$19.00$9.57▼$29.34$3.83B12.03 million shs2.39 million shsASNDAscendis Pharma A/S$202.90-1.1%$183.33$111.09▼$208.16$12.42B0.39490,017 shs329,996 shsQGENQIAGEN$47.08-1.1%$48.65$37.63▼$51.88$10.47B0.641.39 million shs903,884 shsRDYDr. Reddy's Laboratories$14.61+2.5%$14.36$12.26▼$16.19$12.20B0.321.77 million shs679,598 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARWRArrowhead Pharmaceuticals-6.57%+23.33%+65.47%+60.11%+22.28%ASNDAscendis Pharma A/S-0.34%+5.64%+7.17%+19.07%+72.24%QGENQIAGEN+0.17%+2.32%-0.84%+2.97%+10.11%RDYDr. Reddy's Laboratories-0.49%+0.49%+3.26%-10.22%-9.94%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARWRArrowhead Pharmaceuticals 3.00Buy$43.1455.58% UpsideASNDAscendis Pharma A/S 3.00Buy$244.3620.43% UpsideQGENQIAGEN 2.27Hold$49.695.54% UpsideRDYDr. Reddy's Laboratories 2.80Moderate Buy$16.9516.02% UpsideCurrent Analyst Ratings BreakdownLatest ARWR, ASND, RDY, and QGEN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/2/2025ARWRArrowhead PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$80.009/2/2025ASNDAscendis Pharma A/SBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$227.00 ➝ $230.008/19/2025ASNDAscendis Pharma A/SJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$254.00 ➝ $260.008/15/2025RDYDr. Reddy's LaboratoriesZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/11/2025ARWRArrowhead PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/11/2025ARWRArrowhead PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$60.008/8/2025ASNDAscendis Pharma A/SCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/8/2025ASNDAscendis Pharma A/SWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$289.00 ➝ $295.008/8/2025ARWRArrowhead PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$40.00 ➝ $38.008/8/2025ASNDAscendis Pharma A/SCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$243.00 ➝ $290.008/8/2025ASNDAscendis Pharma A/SRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$210.00 ➝ $230.00(Data available from 9/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARWRArrowhead Pharmaceuticals$3.55M1,079.99N/AN/A$1.54 per share18.01ASNDAscendis Pharma A/S$490.75M25.31N/AN/A($1.88) per share-107.93QGENQIAGEN$1.98B5.29$3.17 per share14.84$16.05 per share2.93RDYDr. Reddy's Laboratories$3.81B3.20$1.05 per share13.89$4.73 per share3.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARWRArrowhead Pharmaceuticals-$599.49M-$1.28N/AN/AN/AN/A-40.91%-11.62%11/25/2025 (Estimated)ASNDAscendis Pharma A/S-$409.12M-$5.16N/A845.42N/A-54.94%N/A-24.31%11/13/2025 (Estimated)QGENQIAGEN$83.59M$1.6927.8219.142.5118.30%14.77%8.87%11/5/2025 (Estimated)RDYDr. Reddy's Laboratories$663M$0.6622.1417.825.7916.99%17.25%11.63%11/4/2025 (Estimated)Latest ARWR, ASND, RDY, and QGEN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q3 2025ARWRArrowhead Pharmaceuticals-$0.94-$1.26-$0.32-$1.26$29.01 million$27.77 million8/7/2025Q2 2025ASNDAscendis Pharma A/S-$1.42-$0.93+$0.49-$0.93$163.17 million$216.28 million8/5/2025Q2 2025QGENQIAGEN$0.60$0.60N/A$0.44$523.97 million$533.54 million7/23/2025Q1 25/26RDYDr. Reddy's Laboratories$0.18$0.20+$0.02$0.20$88.27 billion$988.82 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARWRArrowhead PharmaceuticalsN/AN/AN/AN/AN/AASNDAscendis Pharma A/SN/AN/AN/AN/AN/AQGENQIAGEN$0.250.53%N/A14.79%N/ARDYDr. Reddy's Laboratories$0.070.48%N/A10.61%N/ALatest ARWR, ASND, RDY, and QGEN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date6/30/2025RDYDr. Reddy's Laboratoriesannual$0.09150.623832253665189%7/25/20257/10/20258/6/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARWRArrowhead Pharmaceuticals0.394.874.87ASNDAscendis Pharma A/SN/A1.020.69QGENQIAGEN0.251.611.35RDYDr. Reddy's Laboratories0.011.891.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARWRArrowhead Pharmaceuticals62.61%ASNDAscendis Pharma A/SN/AQGENQIAGEN70.00%RDYDr. Reddy's Laboratories3.85%Insider OwnershipCompanyInsider OwnershipARWRArrowhead Pharmaceuticals4.30%ASNDAscendis Pharma A/S40.00%QGENQIAGEN9.00%RDYDr. Reddy's Laboratories2.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARWRArrowhead Pharmaceuticals400138.26 million132.31 millionOptionableASNDAscendis Pharma A/S1,01761.21 million36.73 millionOptionableQGENQIAGEN5,765222.29 million202.29 millionOptionableRDYDr. Reddy's Laboratories27,811834.90 million818.20 millionOptionableARWR, ASND, RDY, and QGEN HeadlinesRecent News About These CompaniesDr. Reddy’s Laboratories Receives USFDA Observations at UK FacilitySeptember 8 at 12:38 PM | msn.comRoyal Bank of Canada Sells 986,447 Shares of Dr. Reddy's Laboratories Ltd $RDYSeptember 5, 2025 | marketbeat.comDr. Reddy's Laboratories Ltd $RDY Shares Sold by Northern Trust CorpSeptember 4, 2025 | marketbeat.comDr. Reddy's Laboratories Ltd $RDY Stake Lowered by OMERS ADMINISTRATION CorpSeptember 2, 2025 | marketbeat.comBNP Paribas Financial Markets Purchases 1,682,363 Shares of Dr. Reddy's Laboratories Ltd $RDYSeptember 2, 2025 | marketbeat.comOLD Mission Capital LLC Has $3.45 Million Stock Position in Dr. Reddy's Laboratories Ltd $RDYSeptember 1, 2025 | marketbeat.comHsbc Holdings PLC Sells 21,500 Shares of Dr. Reddy's Laboratories Ltd $RDYSeptember 1, 2025 | marketbeat.comDr. Reddy's Laboratories Ltd $RDY Shares Acquired by Invesco Ltd.September 1, 2025 | marketbeat.comWellington Management Group LLP Reduces Stock Holdings in Dr. Reddy's Laboratories Ltd $RDYAugust 31, 2025 | marketbeat.comJump Financial LLC Boosts Holdings in Dr. Reddy's Laboratories Ltd $RDYAugust 30, 2025 | marketbeat.comCW Advisors LLC Acquires New Position in Dr. Reddy's Laboratories Ltd $RDYAugust 30, 2025 | marketbeat.comCauseway Capital Management LLC Sells 394,866 Shares of Dr. Reddy's Laboratories Ltd $RDYAugust 28, 2025 | marketbeat.comAmerican Century Companies Inc. Increases Position in Dr. Reddy's Laboratories Ltd $RDYAugust 28, 2025 | marketbeat.comDr. Reddy’s Laboratories Secures Interim Stay on Tax Reassessment OrderAugust 26, 2025 | msn.comVanguard Group Inc. Buys 106,457 Shares of Dr. Reddy's Laboratories Ltd $RDYAugust 26, 2025 | marketbeat.comQuantbot Technologies LP Makes New $1.26 Million Investment in Dr. Reddy's Laboratories Ltd $RDYAugust 25, 2025 | marketbeat.comDeutsche Bank AG Cuts Stock Holdings in Dr. Reddy's Laboratories Ltd $RDYAugust 24, 2025 | marketbeat.comGroupama Asset Managment Buys New Position in Dr. Reddy's Laboratories Ltd $RDYAugust 23, 2025 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Trims Position in Dr. Reddy's Laboratories Ltd $RDYAugust 22, 2025 | marketbeat.comDr. Reddy's Laboratories Ltd (NYSE:RDY) Given Consensus Recommendation of "Moderate Buy" by AnalystsAugust 21, 2025 | marketbeat.comCorient IA LLC Acquires New Holdings in Dr. Reddy's Laboratories Ltd $RDYAugust 20, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARWR, ASND, RDY, and QGEN Company DescriptionsArrowhead Pharmaceuticals NASDAQ:ARWR$27.73 +0.56 (+2.06%) Closing price 04:00 PM EasternExtended Trading$27.84 +0.11 (+0.38%) As of 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.Ascendis Pharma A/S NASDAQ:ASND$202.90 -2.32 (-1.13%) Closing price 04:00 PM EasternExtended Trading$202.90 +0.00 (+0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.QIAGEN NYSE:QGEN$47.08 -0.50 (-1.05%) Closing price 03:59 PM EasternExtended Trading$47.04 -0.04 (-0.08%) As of 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.Dr. Reddy's Laboratories NYSE:RDY$14.61 +0.35 (+2.45%) Closing price 03:59 PM EasternExtended Trading$14.62 +0.01 (+0.03%) As of 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Casey’s General Stores: Investors Win With CASY at the Bat Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver Insiders Sell These High-Quality Stocks: Why Investors Shouldn’t 2 Small-Cap Dividend-Paying Retailers to Buy and Hold for 2026 What August Labor Data Means for the S&P 500 in September Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
